KRMD

$4.27

Post-MarketAs of Mar 17, 8:00 PM UTC

KORU Medical Systems, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$4.27
Potential Upside
5%
Whystock Fair Value$4.48
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Instruments & Supplies

KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to del...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$197.80M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-15.58%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.88

Recent News

Zacks
Mar 17, 2026

KORU Medical Secures EU MDR Certification for Freedom60 Infusion Pump

KRMD secures EU MDR certification for its Freedom60 Infusion Pump, opening broader EU access and boosting adoption of patient-friendly home infusion solutions.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 13, 2026

KORU Medical Systems Inc (KRMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...

KORU Medical Systems Inc (KRMD) reports a 22% revenue increase and new pharma collaborations, despite facing geopolitical and market challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 13, 2026

KORU Medical Systems Q4 Earnings Call Highlights

KORU Medical Systems (NASDAQ:KRMD) reported fourth-quarter and full-year 2025 results that management said reflected continued share gains in its core subcutaneous immunoglobulin (SCIG) business, accelerating international growth, and progress expanding its Freedom Infusion System platform into addi

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 12, 2026

KORU Medical Systems, Inc. (KRMD) Reports Q4 Loss, Beats Revenue Estimates

KORU Medical Systems, Inc. (KRMD) delivered earnings and revenue surprises of +50.00% and +0.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Feb 12, 2026

Down 18.1% in 4 Weeks, Here's Why KORU Medical Systems, Inc. (KRMD) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for KORU Medical Systems, Inc. (KRMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.